Is Tonymoly profitable in 2025?

Yes. TONYMOLY's FY2025 (year ended Dec 31, 2025) consolidated net income was about KRW 11.13-11.4 billion, though down roughly 32% year over year, even as revenue grew 24.45% YoY to KRW 220.27 billion, per company AGM disclosure dated 2026-03-31.

Is Tonymoly stock crashing?

Yes, sharply. TONYMOLY (KRX:214420) shares fell about 45% from a mid-2025 high near KRW 13,600 (June 2025) to below KRW 5,000 by mid-2026, cutting market cap to roughly KRW 108-120 billion (~$80-90M) as of June 24, 2026.

TONYMOLY is founder-controlled. Chairman Bae Hae-dong holds about 34.3% directly, with related family shareholders (Suk-In Jung ~12.7%, Jin-Hyung Bae ~6.3%) pushing insider control above 50%; the National Pension Service holds about 4%, as of January 2026 ownership data.

Could AI replace Tonymoly's business?

Not the brand itself, but AI is reshaping the segment: rival Cosmax runs an AI-diagnosis skincare platform (3WAAU, 2M+ consultations, April 2026) and Amorepacific added in-store AI skin diagnostics in 2025. TONYMOLY shows no public evidence of a comparable AI personalization tool as of mid-2026.

Who is Tonymoly's biggest competitor?

Amorepacific Group (owner of COSRX, Sulwhasoo, Laneige, ~32% domestic share, ~KRW 4.2 trillion revenue in 2024-2025) and LG Household & Health Care are the largest incumbents, while indie challengers APR/Medicube and d'Alba overtook both in market capitalization in 2025, per Korea Herald.

Is Tonymoly's Boncept sub-brand successful?

Yes by volume: Boncept, launched via Daiso Korea in April 2024, had sold over 10 million units by early 2026 and expanded into roughly 1,700 Welcia drugstores in Japan plus Coupang, per company-reported data dated 2026-04-12.

Consumer brands · South Korea

Tonymoly Co., Ltd.

tonymoly.com ↗

South Korean K-beauty brand selling skincare and makeup through Daiso, Welcia, and Coupang.

Losing its protection

Assessed 26 July 2026 · Evidence as of 26 July 2026

The structural protection is eroding.

On the recordSince 26 July 2026 · Checkable from August 14, 2026 · Every call on the record Checkpoint: Next scheduled earnings report

The call

Tonymoly keeps growing sales through solid distribution deals, but profit is shrinking and it has no data or AI tool to match what bigger rivals now offer shoppers.

Tonymoly makes affordable Korean skincare and cosmetics sold through major drugstore chains in Korea and Japan, plus online. Bigger companies like Amorepacific and LG can copy its products and undercut prices anytime, and newer brands like COSRX and Beauty of Joseon are already winning over customers by offering personalized skincare advice through apps and AI tools that Tonymoly does not have. The company could change its situation if it builds its own data system to understand what each customer's skin needs, or if it can lock in exclusive deals with major retailers like Ulta in America so rivals cannot easily sell in the same stores.

Why

AI pressure: Cosmax's 3WAAU and Amorepacific's New Beauty AI skin-diagnostic tools. Rivals now offer AI skin scans that pick products for shoppers; Tonymoly has no such tool, so it just sells shelf items. Could AI do the core job? Only partly.

Bigger players: Amorepacific Group (owns COSRX) and LG Household & Health Care. Amorepacific's COSRX and LG H&H already compete in the same value tier Tonymoly relies on for volume. Could a giant copy it? Yes, easily.

What protects it. A profitable 20-year brand with real shelf space: 10M+ Boncept units through Daiso, 1,700 Welcia stores in Japan, plus an exclusive ITOCHU distribution deal.

What would change this call

Whether Boncept secures shelf space at Ulta or Sephora in the US within 12 months. Would show Tonymoly building an owned distribution channel, not just riding rival-copyable shelves.
Whether Tonymoly posts two more quarters of rising revenue but falling net income after FY2025's drop. Would confirm margin erosion from price competition despite topline growth.
Whether Tonymoly announces its own skin-data or AI-personalization tool or acquisition within a year. Would show it closing the tech gap with Amorepacific's New Beauty and Cosmax's 3WAAU.

Key numbers

FY2025 revenue KRW 220.27B, up 24.45% YoY (2025-12-31)
FY2025 net income ~KRW 11.3B, down 32% YoY (2025-12-31)
Stock down 45% from June 2025 high to mid-2026 (2026-06-24)

Named risks

Stock down ~45% from mid-2025 high to below KRW5,000 by mid-2026. Severity: high
Net income falling (-32% YoY FY2025) despite revenue growth, signaling margin compression. Severity: medium
No proprietary AI or consumer skin-data personalization capability versus Cosmax and Amorepacific. Severity: medium
Absence from AI answer-engine product citations compared to COSRX and Beauty of Joseon as of July 2026. Severity: medium
Low shareholder quorum (~26.5%) on some March 2026 AGM audit committee votes signals governance friction. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Amorepacific Group	losing to	Amorepacific holds ~32% domestic share and ~KRW4.2T revenue (2024-2025), deploys AI in-store diagnostics
COSRX (Amorepacific-owned)	losing to	Amorepacific acquired 93.2% of COSRX for ~KRW935B by 2023, contesting the same value/indie lane
APR Co. (Medicube) and d'Alba Global	losing to	Overtook Amorepacific and LG H&H in market cap as of Sept 2025, per Korea Herald
Beauty of Joseon, Anua, Skin1004 (Goodai roll-up)	gaining on	Fast-rising indie brands cited by AI answer engines over TONYMOLY as of July 2026
LG Household & Health Care	contesting	LG H&H itself posted first cosmetics deficit in 21 years, Q2 2025, weakening a shared incumbent rival
Cosmax (ODM supplier/rival platform)	losing to	Cosmax's AI-prescription platform 3WAAU passed 2M consultations and expanded to Japan JV, April 2026

Questions people ask

Is Tonymoly profitable in 2025?: Yes. TONYMOLY's FY2025 (year ended Dec 31, 2025) consolidated net income was about KRW 11.13-11.4 billion, though down roughly 32% year over year, even as revenue grew 24.45% YoY to KRW 220.27 billion, per company AGM disclosure dated 2026-03-31.
Is Tonymoly stock crashing?: Yes, sharply. TONYMOLY (KRX:214420) shares fell about 45% from a mid-2025 high near KRW 13,600 (June 2025) to below KRW 5,000 by mid-2026, cutting market cap to roughly KRW 108-120 billion (~$80-90M) as of June 24, 2026.
Who owns Tonymoly?: TONYMOLY is founder-controlled. Chairman Bae Hae-dong holds about 34.3% directly, with related family shareholders (Suk-In Jung ~12.7%, Jin-Hyung Bae ~6.3%) pushing insider control above 50%; the National Pension Service holds about 4%, as of January 2026 ownership data.
Could AI replace Tonymoly's business?: Not the brand itself, but AI is reshaping the segment: rival Cosmax runs an AI-diagnosis skincare platform (3WAAU, 2M+ consultations, April 2026) and Amorepacific added in-store AI skin diagnostics in 2025. TONYMOLY shows no public evidence of a comparable AI personalization tool as of mid-2026.
Who is Tonymoly's biggest competitor?: Amorepacific Group (owner of COSRX, Sulwhasoo, Laneige, ~32% domestic share, ~KRW 4.2 trillion revenue in 2024-2025) and LG Household & Health Care are the largest incumbents, while indie challengers APR/Medicube and d'Alba overtook both in market capitalization in 2025, per Korea Herald.
Is Tonymoly's Boncept sub-brand successful?: Yes by volume: Boncept, launched via Daiso Korea in April 2024, had sold over 10 million units by early 2026 and expanded into roughly 1,700 Welcia drugstores in Japan plus Coupang, per company-reported data dated 2026-04-12.

Timeline

2026-04Boncept sub-brand surpasses 10 million units sold via Daiso Korea
2026-03-31AGM approves FY2025 financials, KRW 50/share dividend; some audit votes had ~26.5% quorum
2025-12-31FY2025 revenue reaches KRW 220.27B (+24.45% YoY); net income falls ~32% to ~KRW 11.3B
2025-06-12Tonymoly launches 'Uncommon Crew' influencer ambassador program
2025-04-24Tonymoly exhibits at Ulta Beauty World with Squishmallow collaboration
2024-04Boncept sub-brand launches at Daiso Korea value retail stores
2023-03ITOCHU exclusive Japan distribution partnership for TONYMOLY takes effect
2023-02-14ITOCHU announces acquisition of exclusive rights to sell TONYMOLY in Japan

Revision history

26 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

PVH VF Kering